- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00719797
Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (TRIBE)
A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.
PURPOSE: This randomized phase III trial is comparing two combination chemotherapy regimens given together with bevacizumab to see how well they work as first-line therapy in treating patients with metastatic colorectal cancer that cannot be removed by surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- To compare the progression-free survival of bevacizumab in combination with oxaliplatin, irinotecan hydrochloride, fluorouracil, and leucovorin calcium (FOLFOXIRI) versus bevacizumab in combination with irinotecan hydrochloride, fluorouracil, and leucovorin calcium (FOLFIRI) in patients with unresectable, metastatic colorectal cancer.
Secondary
- To evaluate the safety profile, including long-term adverse events of these regimens in these patients.
- To compare the overall response rate, duration of response, and secondary R0 surgery rates of metastases and overall survival between treatment arms.
- To evaluate potential surrogate markers predictive of bevacizumab activity.
OUTLINE: This is a multicenter study. Patients are stratified according to ECOG performance status (0 vs 1-2), prior adjuvant chemotherapy (yes vs no), and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I (FOLFOXIRI): Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
- Arm II (FOLFIRI): Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
In both arms, treatment repeats every 2 weeks for up to 12 courses. Treatment with bevacizumab, fluorouracil, and leucovorin calcium continues in the absence of disease progression or unacceptable toxicity.
Patients undergo serum extraction and blood sample collection periodically for genotyping studies. Patients also undergo collection of tumoral sections from paraffin embedded primary and/or metastatic lesions periodically for immunohistochemical analyses.
After completion of study treatment, patients are followed every 8 weeks.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Alessandria, Italia, 15100
- Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al) Oncologia Medica
-
Ancona, Italia, 60100
- A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona - Ancona (An) Oncologia Medica
-
Arezzo, Italia, 52100
- P.O. Zona Aretina - Ospedale S. Donato Di Arezzo - Arezzo (Ar) Oncologia Medica
-
Aviano, Italia, 33081
- Irccs Centro Di Riferimento Oncologico (Cro) - Aviano (Pn) Oncologia Medica
-
Brescia, Italia, 25122
- Ospedale S. Orsola F.B.F. - Brescia - Brescia (Bs) Oncologia Medica
-
Brescia, Italia, 25124
- Istituto Ospedaliero Fondazione Poliambulanza Di Brescia - Brescia (Bs) Oncologia Medica
-
Brindisi, Italia, 72100
- Stabilimento "Perrino" - Brindisi - Brindisi (Br) Oncologia Medica
-
Caltanissetta, Italia, 93100
- Azienda Ospedaliera S. Elia - Caltanissetta (Cl) Oncologia Medica
-
Carrara, Italia, 54033
- Ausl 1 Di Massa E Carrara - Carrara (Ms) Oncologia Medica
-
Cecina, Italia, 57023
- Ospedale Cecina - Cecina (Li) Oncologia Medica
-
Cremona, Italia, 26100
- Istituti Ospitalieri - Cremona - Cremona (Cr) Oncologia Medica
-
Cuneo, Italia, 12100
- Azienda Ospedaliera S. Croce E Carle Di Cuneo - Cuneo (Cn) Oncoematologia
-
Empoli, Italia, 50053
- Ausl 11 Di Empoli (Fi) - Empoli (Fi) Oncologia Medica
-
Fabriano, Italia, 60044
- U.S.L.N.6 -Ospedale Civile 'E.Profili'-F - Fabriano (An) Oncologia Medica
-
Firenze, Italia, 50122
- Ausl 10 Di Firenze - Firenze (Fi) Oncologia Medica
-
Genova, Italia, 16132
- Irccs Istituto Nazionale Per La Ricerca Sul Cancro (Ist) - Genova (Ge) Oncologia Medica
-
Lecce, Italia, 73100
- Ausl Le Di Lecce - Lecce (Le) Oncologia Medica
-
Legnano, Italia, 37045
- Aulss 21 Di Legnago (Vr) - Legnago (Vr) Oncologia Medica
-
Lido di Camaiore, Italia, 55053
- Ausl 12 Di Viareggio (Lu) - Lido Di Camaiore (Lu) Oncologia Medica
-
Livorno, Italia, 57100
- Ospedale Livorno - Livorno (Li), Oncologia Medica
-
Lucca, Italia, 25124
- Presidio Ospedaliero Piana Di Lucca - Lucca (Lu) Oncologia Medica
-
Milano, Italia, 20132
- Irccs Fondazione Centro S. Raffaele Del Monte Tabor - Milano (Mi) Oncologia Medica
-
Milano, Italia, 20162
- Ospedale Ca' Granda-Niguarda - Milano - Milano (Mi) Oncologia Medica
-
Monza, Italia, 20052
- S.Gerardo - Monza - Monza (Mi) Oncologia Medica
-
Napoli, Italia, 80131
- A.O. Universitaria Federico Ii Di Napoli Oncologia Medica
-
Novara, Italia, 28100
- A.O. Universitaria Maggiore Della Carita' Di Novara Oncologia Medica
-
Parma, Italia, 43100
- A.O. Universitaria Di Parma Oncologia Medica
-
Perugia, Italia, 06012
- Asl 1 Di Citta' Di Castello (Pg) - Citta' Di Castello (Pg) Oncologia Medica
-
Perugia, Italia, 06156
- A.O. Di Perugia - Ospedale S. Maria Della Misericordia (Ex Silvestrini) - Perugia (Pg) Oncologia Medica
-
Pesaro, Italia, 61100
- Azienda Ospedaliera San Salvatore - Pesaro (Pu) Oncologia Medica
-
Pescia, Italia, 51017
- Ospedale Della Valdinievole - Pescia (Pt) Oncologia Medica
-
Piombino, Italia, 57100
- Ospedale Piombino - Piombino (Li) Oncologia Medica
-
Pisa, Italia, 56100
- Ausl 5 Di Pisa - Pisa (Pi) Oncologia Medica
-
Pisa, Italia, 56100
- A.O. Universitaria Pisana Oncologia Medica
-
Pisa, Italia, 56126
- Alfredo Falcone A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica
-
Pistoia, Italia, 51100
- Ausl 3 Di Pistoia - Pistoia (Pt) Oncologia Medica
-
Prato, Italia, 59100
- Ausl 4 Di Prato - Prato (Po) Oncologia Medica
-
Reggio Emilia, Italia, 42100
- Ospedale Di S. Maria Nuova - Reggio Nell'Emilia (Re) Oncologia Medica
-
Rome, Italia, 00155
- Policlinico Universitario Campus Bio-Medico Di Roma Oncologia Medica
-
Rome, Italia, 00161
- Policlinico Umberto I Di Roma Oncologia Medica
-
Rome, Italia, 00168
- Policlinico Universitario Gemelli Di Roma Oncologia Medica
-
Siena, Italia, 53100
- A.O. Universitaria Senese Oncologia Medica
-
Sondrio, Italia, 23100
- Ospedale Civile - Sondrio - Sondrio (So) Oncologia Medica
-
Torino, Italia, 10134
- A.O. Universitaria S. Giovanni Battista-Molinette Di Torino Oncologia Medica
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically confirmed colorectal cancer
- Unresectable metastatic disease
- Measurable disease, defined as ≥ 1 measurable lesion according to RECIST criteria
- No prior chemotherapy for metastatic disease
- No untreated brain metastases, spinal cord compression, or primary brain tumors
- No history or evidence of CNS disease by physical examination unless adequately treated (e.g., uncontrolled seizure despite standard medical therapy or history of stroke)
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status (PS) 0-2 (≤ 70 years of age) OR ECOG PS 0 (71-75 years of age)
- Life expectancy ≥ 12 weeks
- Neutrophils ≥ 1.5 x 10^9/L
- Platelet count ≥ 100 x 10^9/L
- Hemoglobin > 9 g/dL
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN if f liver metastases present)
- Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases present)
- Creatinine clearance > 50 mL/min OR serum creatinine ≤ 1.5 times ULN
- Proteinuria < 2+ by dipstick OR urine protein ≤ 1 g by 24-hr urine collection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Exclusion criteria:
- Serious, nonhealing wound, ulcer, or bone fracture
- Evidence of bleeding diathesis or coagulopathy
- Uncontrolled hypertension
Clinically significant (i.e., active) cardiovascular disease, including any of the following:
- Cerebrovascular accidents within the past 6 months
- Myocardial infarction within the past 6 months
- Unstable angina
- New York Heart Association class II-IV congestive heart failure
- Serious cardiac arrhythmia requiring medication
- Known allergy to Chinese hamster ovary cell proteins or any of the components of the study medications
- Other co-existing malignancy or malignancy diagnosed within the past 5 years, except for basal cell or squamous cell carcinoma, or carcinoma in situ of the cervix
- Symptomatic peripheral neuropathy ≥ grade 1 according to the NCI Common Toxicity Criteria
- Lack of physical integrity of the upper gastrointestinal tract
- Malabsorption syndrome
- Inability to take oral medication
- Significant traumatic injury within the past 28 days
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 4 weeks since prior radiotherapy
- More than 10 days since prior and no concurrent ongoing treatment with anticoagulants for therapeutic purposes
- More than 28 days since prior and no concurrent major surgical procedure
- More than 28 days since prior open biopsy
- More than 30 days since prior investigational agents
- No concurrent chronic daily high-dose acetylsalicylic acid (> 325 mg/day)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm I (FOLFOXIRI)
Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1.
Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
|
Dado IV
Dado IV
Dado IV
Dado IV
Dado IV
|
Experimental: Arm II (FOLFIRI)
Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1.
Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
|
Dado IV
Dado IV
Dado IV
Dado IV
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression free survival
Periodo de tiempo: up to 54 months
|
To compare the progression free survival of bevacizumab in combination with oxaliplatin, irinotecan and infusional 5FU/LV ("GONO" FOLFOXIRI regimen) to bevacizumab in combination with irinotecan and infusional 5FU/LV (FOLFIRI regimen)
|
up to 54 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Overall response rate
Periodo de tiempo: up to 54 months
|
up to 54 months
|
Duration of response
Periodo de tiempo: up to 54 months
|
up to 54 months
|
Secondary R0 surgery rates of metastases
Periodo de tiempo: up to 54 months
|
up to 54 months
|
Overall survival
Periodo de tiempo: up to 54 months
|
up to 54 months
|
Surrogate markers predictive of bevacizumab activity
Periodo de tiempo: up to 54 months
|
up to 54 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Alfredo Falcone, MD, Presidio Ospedaliero di Livorno
Publicaciones y enlaces útiles
Publicaciones Generales
- Tokunaga R, Cao S, Naseem M, Lo JH, Battaglin F, Puccini A, Berger MD, Soni S, Millstein J, Zhang W, Stintzing S, Loupakis F, Cremolini C, Heinemann V, Falcone A, Lenz HJ. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clin Colorectal Cancer. 2019 Mar;18(1):e8-e19. doi: 10.1016/j.clcc.2018.09.003. Epub 2018 Sep 13.
- Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.
- Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Online ahead of print.
- Rossini D, Germani MM, Lonardi S, Pietrantonio F, Dell'Aquila E, Borelli B, Allegrini G, Maddalena G, Randon G, Marmorino F, Zaniboni A, Buonadonna A, Boccaccino A, Conca V, Antoniotti C, Passardi A, Masi G, Cremolini C. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022 Jul;170:64-72. doi: 10.1016/j.ejca.2022.04.019. Epub 2022 May 17.
- Antoniotti C, Germani MM, Rossini D, Lonardi S, Pietrantonio F, Santini D, Marmorino F, Allegrini G, Daniel F, Raimondi A, Borelli B, Zaniboni A, Conca V, Abraham J, Spetzler D, Maiello E, Boccaccino A, Passardi A, Giordano M, Tamburini E, Korn MW, Masi G, Cremolini C. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. Eur J Cancer. 2022 May;167:23-31. doi: 10.1016/j.ejca.2022.02.031. Epub 2022 Mar 30.
- Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.
- Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, Borelli B, Marmorino F, Citi V, Cortesi E, Moretto R, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Ricci V, Di Donato S, Zagonel V, Boni L, Falcone A, Danesi R. DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.
- Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.
- Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.
- Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.
- Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes Protectores
- Inhibidores de la topoisomerasa
- Agentes antineoplásicos inmunológicos
- Inhibidores de la angiogénesis
- Agentes moduladores de la angiogénesis
- Sustancias de crecimiento
- Inhibidores del crecimiento
- Micronutrientes
- Vitaminas
- Hormonas y agentes reguladores del calcio
- Inhibidores de la topoisomerasa I
- Antídotos
- Complejo de vitamina B
- Fluorouracilo
- Oxaliplatino
- Bevacizumab
- Leucovorina
- Irinotecán
- Calcio
- Levoleucovorina
Otros números de identificación del estudio
- CDR0000598582
- GONO-TRIBE
- ASL608LIOM04
- EUDRACT:2008-001537-10
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer colonrectal
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre bevacizumab
-
National Cancer Institute (NCI)Activo, no reclutandoCarcinoma de trompa de Falopio recidivante | Carcinoma de ovario recurrente | Carcinoma peritoneal primario recidivante | Cistadenocarcinoma de células claras de ovario | Adenocarcinoma endometrioide de ovario | Cistadenocarcinoma seroso de ovario | Adenocarcinoma de células claras endometriales | Adenocarcinoma seroso endometrial y otras condicionesEstados Unidos
-
National Cancer Institute (NCI)NRG OncologyTerminadoGlioblastoma | Gliosarcoma | Glioblastoma recurrente | Oligodendroglioma | Glioblastoma de células gigantes | Neoplasia cerebral recurrenteEstados Unidos, Canadá
-
National Cancer Institute (NCI)Activo, no reclutandoAdenocarcinoma endometrioide de ovario | Adenocarcinoma seroso peritoneal primario de alto grado | Adenocarcinoma endometrioide de las trompas de Falopio | Carcinoma de las trompas de Falopio resistente al platino | Carcinoma peritoneal primario resistente al platino | Adenocarcinoma seroso... y otras condicionesEstados Unidos, Canadá
-
M.D. Anderson Cancer CenterReclutamientoCarcinoma hepatocelular en estadio IB AJCC v8 | Carcinoma hepatocelular en estadio II AJCC v8 | Carcinoma hepatocelular resecable | Carcinoma hepatocelular en estadio I AJCC v8 | Carcinoma hepatocelular en estadio IA AJCC v8Estados Unidos
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)ReclutamientoCarcinoma de trompa de Falopio recidivante | Carcinoma de ovario recurrente | Carcinoma peritoneal primario recidivante | Adenocarcinoma endometrioide de ovario | Adenocarcinoma de células claras de ovario | Adenocarcinoma de las trompas de Falopio | Adenocarcinoma seroso de las trompas de Falopio y otras condicionesEstados Unidos
-
National Cancer Institute (NCI)Activo, no reclutandoMelanoma cutáneo en estadio IV AJCC v6 y v7 | Melanoma cutáneo en estadio IIIC AJCC v7 | Melanoma irresecableEstados Unidos
-
National Cancer Institute (NCI)TerminadoAdenocarcinoma de cuello uterino | Carcinoma adenoescamoso de cuello uterino | Carcinoma de células escamosas de cuello uterino, no especificado | Cáncer de cuello uterino en estadio IVA AJCC v6 y v7 | Carcinoma cervical recurrente | Cáncer de cuello uterino en estadio IV AJCC v6 y v7 | Cáncer...Estados Unidos
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsReclutamientoCarcinoma de trompa de Falopio recidivante | Carcinoma de ovario recurrente | Carcinoma peritoneal primario recidivante | Adenocarcinoma seroso endometrial recidivante | Adenocarcinoma de células claras de ovario | Carcinoma de ovario resistente al platino recurrente | Carcinoma de ovario sensible... y otras condicionesEstados Unidos
-
National Cancer Institute (NCI)ReclutamientoSarcoma alveolar metastásico de partes blandas | Sarcoma alveolar de partes blandas irresecableEstados Unidos
-
City of Hope Medical CenterNational Cancer Institute (NCI)Activo, no reclutandoCarcinoma de células no pequeñas de pulmón metastásico | Cáncer de pulmón en estadio IVA AJCC v8 | Cáncer de pulmón en estadio IVB AJCC v8 | Cáncer de pulmón en estadio III AJCC v8 | Cáncer de pulmón en estadio IV AJCC v8 | Cáncer de pulmón en estadio IIIA AJCC v8 | Cáncer de pulmón en estadio... y otras condicionesEstados Unidos